Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 592

Sort by

Sort Order Select

Journal Articles

Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis

Blood (2019) 134 (Supplement_1): 3982.

https://doi.org/10.1182/blood-2019-124783

Published: 2019

Journal Articles

A Phase II Study of Lenalidomide Plus Rituximab in Patients with Newly Diagnosed Follicular Lymphoma: An Interim Analysis

Zhong Zheng, Li Wang, MD PhD, Shu Cheng, Pengpeng Xu, Weili Zhao, MD PhD

Blood (2019) 134 (Supplement_1): 3984.

https://doi.org/10.1182/blood-2019-126667

Published: 2019

Journal Articles

The 'Real World' Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative

Allison Barraclough, Edward Yoo, Chan Y. Cheah, Dipti Talaulikar, Bianca Nguyen, Michelle Turner, Fatima Tahir, Jing Huang, Colm Keane, MD, Mitchel Lincoln, Tara Cochrane, Anna M. Johnston, Michael Dickinson, MBBS,FRACP,FRCPA, Stephen Opat, Zoe McQuilten, Erica M. Wood, Gayathri St George, Cameron Wellard, Eliza A Hawkes

Blood (2019) 134 (Supplement_1): 3986.

https://doi.org/10.1182/blood-2019-129294

Published: 2019

Journal Articles

Coexistence of B-Cell Dyscrasia with Large Granular Lymphocytic Leukemia

Hassan Awada, Jibran Durrani, Ashwin Kishtagari, MBBS, Valeria Visconte, PhD, Reda Z. Mahfouz, MD PhD

Blood (2019) 134 (Supplement_1): 3750.

https://doi.org/10.1182/blood-2019-132220

Published: 2019

Journal Articles

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Ga-Young Song, Seok Jin Kim, MD PhD, Sang Eun Yoon, Jin Seok Kim, MD PhD, Ho-Young Yhim, MD PhD, Youngil Koh, MD PhD, Sung Yong Oh, MD PhD, Ho Sup Lee, MD PhD, Ho-Jin Shin, MD PhD, Young Rok Do, MD PhD, Won Sik Lee, MD PhD, Lee Gyeong-Won, Dae Sik Kim, Yong Park, Deok-Hwan Yang, MD PhD

Blood (2019) 134 (Supplement_1): 4002.

https://doi.org/10.1182/blood-2019-126574

Published: 2019

Journal Articles

Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival in Patients with Low Tumor Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab

Jonathan W. Friedberg, MD, Michael T. Brady, PhD, Myla Strawderman, MS, Brad S. Kahl, MD, John P. Leonard, MD, Izidore S. Lossos, MD, Christopher R. Flowers, MD MS, Grerk Sutamtewagul, MD, Jonathon B. Cohen, MDMS, Derick R. Peterson, PhD, Loretta J. Nastoupil, MD MSc

Blood (2019) 134 (Supplement_1): 4008.

https://doi.org/10.1182/blood-2019-127320

Published: 2019

Journal Articles

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Pier Luigi Zinzani, MD, Armando Santoro, Luigina Mollica, MD FRCPC, PhD, Sirpa Leppä, MD PhD, George A Follows, MD PhD, Georg Lenz, MD, Won Seog Kim, MD PhD, Arnon Nagler, MD MSc, Panayiotis Panayiotidis, MD, Judit Demeter, MD PhD Dr. Sci, Franck Morschhauser, MD, Javier Munoz, MD MS, FACP, Ashok Miriyala, MD, Alice Benson, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Martin Dreyling, MD

Blood (2019) 134 (Supplement_1): 4009.

https://doi.org/10.1182/blood-2019-131779

Published: 2019

Journal Articles

Splenic Marginal Zone Lymphoma: A U.S Population-Based Survival Analysis (1997-2016)

Jorge Florindez, MD MS, Juan Pablo Alderuccio, MD, Izidore S. Lossos, MD

Blood (2019) 134 (Supplement_1): 4014.

https://doi.org/10.1182/blood-2019-127688

Published: 2019

Journal Articles

Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation

Clarisse Cazelles, Karim Belhadj, Helene Vellemans, Vincent Camus, Christiane Copie, MD PhD, Liana Veresezan, MD, Emmanuel Itti, MD PhD, Stephanie Becker, MD, Muriel verlinde Carvalho, Jehan Dupuis, MD, Fabien Le Bras, Francois Lemonnier, MD PhD, Louise Roulin, MD, Taoufik El Gnaoui, Fabrice Jardin, Nicolas Mounier, MD, Herve Tilly, MD PhD, Corinne Haioun, MD PhD

Blood (2019) 134 (Supplement_1): 4115.

https://doi.org/10.1182/blood-2019-124143

Published: 2019

Journal Articles

Clinical, Immunophenotypic and Genetic Characteristics of Aggressive (non-Burkitt) B-Cell Lymphoma in a Real Life Cohort

Blood (2019) 134 (Supplement_1): 4122.

https://doi.org/10.1182/blood-2019-123259

Published: 2019

Journal Articles

Prognostic Value of Disease Risk Score Versus Gait Speed in Older Adults with Lymphoma

Lee Mozessohn, MD, Liying Zhang, PhD, Oreofe O. Odejide, MD MPH, Anna M. Tanasijevic, MPH, Richard Chen, BA, Rena Buckstein, MD FRCPC, Robert J. Soiffer, MD, Jorge J Castillo, MD, Andrew Keezer, BS, Jane Driver, MD MPH, Gregory A. Abel, MDMPH

Blood (2019) 134 (Supplement_1): 68.

https://doi.org/10.1182/blood-2019-124946

Published: 2019

Journal Articles

Prediction of High-Risk Group of Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using a CT-Based Radiomics Model with Machine Learning

Raoul Santiago, MDMSc, Johanna Ortiz Jimenez, MD, Reza Forghani, MD PhD, Nikesh Muthukrishnan, MEng, Olivier Del Corpo, BSC, MSc, Shairabi Karthigesu, Muhammad Yahya Haider, Caroline Reinhold, MD MSc, Sarit Assouline, MD

Blood (2019) 134 (Supplement_1): 4136.

https://doi.org/10.1182/blood-2019-126745

Published: 2019

Journal Articles

Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001

Donald L. Patrick, Annette Powers, Monika Parisi, Yeonhee Kim, Jacob Garcia, MD, Christine Dehner, David G. Maloney, MD PhD

Blood (2019) 134 (Supplement_1): 66.

https://doi.org/10.1182/blood-2019-127145

Published: 2019

Journal Articles

Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance

Jonas Paludo, MD, Surendra Dasari, PhD, Kerstin Wenzl, PhD, Shahrzad Jalali, PhD, Jordan Krull, Michelle Manske, MS, BS, Esteban Braggio, PhD, Prashant Kapoor, MD, Aneel Paulus, MD, Sikander Ailawadhi, MD, Craig B. Reeder, MD, Allison C. Rosenthal, DO, Robert A. Kyle, MD, Morie A Gertz, MD, Anne J Novak, PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 2774.

https://doi.org/10.1182/blood-2019-128912

Published: 2019

Journal Articles

Glycolytic Biomarkers Predictive of Transformation in Patients with Follicular Lymphoma

Ida Monrad, MSc, Charlotte Madsen, Kristina Lauridsen, Bent Honoré, Trine Lindhardt Plesner, Stephen Hamilton-Dutoit, MD, Francesco d'Amore, MD, Maja Ludvigsen, MSc, PhD

Blood (2019) 134 (Supplement_1): 2805.

https://doi.org/10.1182/blood-2019-122651

Published: 2019

Journal Articles

B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL

Clare Gould, Colm Keane, MD, Valentine Murigneux, M.Sc., Harald Oey, Jonathan Ellis, PhD, Simone Birch, MBBS, Jay Gunawardana, PhD, Dipti Talaulikar, Mark S. Hertzberg, MD PhD, Kimberley Jones, Maher K. Gandhi, PhD

Blood (2019) 134 (Supplement_1): 2778.

https://doi.org/10.1182/blood-2019-126537

Published: 2019

Journal Articles

Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting

David Andorsky, MD, Rebecca J Chan, MD PhD, Jamyia Clark, MPH, Bianca Ruzicka, PhD, Nicholas James Robert, MD, Farrukh T. Awan, MD

Blood (2019) 134 (Supplement_1): 2810.

https://doi.org/10.1182/blood-2019-124013

Published: 2019

Journal Articles

Long-Term Follow-up of Follicular Lymphoma (FL) Patients (pts) Demonstrating Undetectable Minimal Residual Disease (MRD) Using a Next-Generation Based DNA Assay: Support for FL As a Curable Disease

Maryam Sarraf Yazdy, MD, Umair Jarral, MD, Chao Yin, MD, Frank Kuhr, PhD, Allison P. Jacob, Bruce D. Cheson, MD

Blood (2019) 134 (Supplement_1): 2813.

https://doi.org/10.1182/blood-2019-127262

Published: 2019

Journal Articles

Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

Adam J Olszewski, MD, Thomas A Ollila, MD, John L. Reagan, MD

Blood (2019) 134 (Supplement_1): 2824.

https://doi.org/10.1182/blood-2019-121841

Published: 2019

Journal Articles

Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study

Laurie H Sehn, MD, Marek Trněný, MD, Kamal Bouabdallah, MD, Gregory Dueck, MD, John G. Gribben, MD DSc, P.J. Lugtenburg, MD PhD, Gilles A. Salles, MD PhD, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Wenxin Liu, PhD, Bruce D. Cheson, MD

Blood (2019) 134 (Supplement_1): 2822.

https://doi.org/10.1182/blood-2019-123422

Published: 2019

NARROW

Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis

A Phase II Study of Lenalidomide Plus Rituximab in Patients with Newly Diagnosed Follicular Lymphoma: An Interim Analysis

The 'Real World' Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative

Coexistence of B-Cell Dyscrasia with Large Granular Lymphocytic Leukemia

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival in Patients with Low Tumor Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Splenic Marginal Zone Lymphoma: A U.S Population-Based Survival Analysis (1997-2016)

Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation

Clinical, Immunophenotypic and Genetic Characteristics of Aggressive (non-Burkitt) B-Cell Lymphoma in a Real Life Cohort

Prognostic Value of Disease Risk Score Versus Gait Speed in Older Adults with Lymphoma

Prediction of High-Risk Group of Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using a CT-Based Radiomics Model with Machine Learning

Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001

Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance

Glycolytic Biomarkers Predictive of Transformation in Patients with Follicular Lymphoma

B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL

Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting

Long-Term Follow-up of Follicular Lymphoma (FL) Patients (pts) Demonstrating Undetectable Minimal Residual Disease (MRD) Using a Next-Generation Based DNA Assay: Support for FL As a Curable Disease

Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only